Back to Search Start Over

Fusion peptide of HIV-1 as a site of vulnerability to neutralizing antibody.

Authors :
Kong R
Xu K
Zhou T
Acharya P
Lemmin T
Liu K
Ozorowski G
Soto C
Taft JD
Bailer RT
Cale EM
Chen L
Choi CW
Chuang GY
Doria-Rose NA
Druz A
Georgiev IS
Gorman J
Huang J
Joyce MG
Louder MK
Ma X
McKee K
O'Dell S
Pancera M
Yang Y
Blanchard SC
Mothes W
Burton DR
Koff WC
Connors M
Ward AB
Kwong PD
Mascola JR
Source :
Science (New York, N.Y.) [Science] 2016 May 13; Vol. 352 (6287), pp. 828-33.
Publication Year :
2016

Abstract

The HIV-1 fusion peptide, comprising 15 to 20 hydrophobic residues at the N terminus of the Env-gp41 subunit, is a critical component of the virus-cell entry machinery. Here, we report the identification of a neutralizing antibody, N123-VRC34.01, which targets the fusion peptide and blocks viral entry by inhibiting conformational changes in gp120 and gp41 subunits of Env required for entry. Crystal structures of N123-VRC34.01 liganded to the fusion peptide, and to the full Env trimer, revealed an epitope consisting of the N-terminal eight residues of the gp41 fusion peptide and glycan N88 of gp120, and molecular dynamics showed that the N-terminal portion of the fusion peptide can be solvent-exposed. These results reveal the fusion peptide to be a neutralizing antibody epitope and thus a target for vaccine design.<br /> (Copyright © 2016, American Association for the Advancement of Science.)

Details

Language :
English
ISSN :
1095-9203
Volume :
352
Issue :
6287
Database :
MEDLINE
Journal :
Science (New York, N.Y.)
Publication Type :
Academic Journal
Accession number :
27174988
Full Text :
https://doi.org/10.1126/science.aae0474